R R

What Is Rezdiffra?

Rezdiffra is a prescription oral medication containing resmetirom, a thyroid hormone receptor-beta agonist. It is approved for adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly called nonalcoholic steatohepatitis, who have moderate to advanced liver fibrosis consistent with stages F2 to F3. Rezdiffra is used alongside diet and exercise to address liver disease associated with fat accumulation, inflammation, and scarring. It received FDA accelerated approval based on improvements in liver inflammation and fibrosis. Continued approval may depend on confirmatory evidence of clinical benefit. Rezdiffra is not approved for all forms or stages of fatty liver disease.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Rezdiffra?

Rezdiffra is a prescription oral medication containing resmetirom, a thyroid hormone receptor-beta agonist. It is approved for adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly called nonalcoholic steatohepatitis, who have moderate to advanced liver fibrosis consistent with stages F2 to F3. Rezdiffra is used alongside diet and exercise to address liver disease associated with fat accumulation, inflammation, and scarring. It received FDA accelerated approval based on improvements in liver inflammation and fibrosis. Continued approval may depend on confirmatory evidence of clinical benefit. Rezdiffra is not approved for all forms or stages of fatty liver disease.

read more about rezdiffra ...

Copy this HTML:

Copy HTML Copied!

How Does Rezdiffra Work?

Rezdiffra activates thyroid hormone receptor-beta, which is expressed in the liver and participates in regulating lipid metabolism. By stimulating this receptor, resmetirom affects pathways involved in the processing and breakdown of fats within liver cells. These actions can reduce liver fat and improve certain tissue findings associated with metabolic dysfunction-associated steatohepatitis. Rezdiffra is designed to act preferentially on the beta receptor rather than broadly replacing thyroid hormone. Its complete long-term effects on liver-related clinical outcomes are still being evaluated. Treatment is combined with dietary and physical activity measures rather than replacing them.

What Liver Condition Does Rezdiffra Treat?

Rezdiffra is approved for adults with noncirrhotic MASH and moderate to advanced liver fibrosis, consistent with stages F2 or F3. MASH involves excess liver fat accompanied by inflammation and liver cell injury, which can lead to scarring. The medication is not indicated for simple fatty liver without the required disease characteristics or for established cirrhosis. Rezdiffra should be avoided in patients with decompensated cirrhosis and in those with moderate to severe hepatic impairment. A liver specialist evaluates the diagnosis, degree of fibrosis, liver function, and other medications before prescribing treatment. Its approval remains under the accelerated approval pathway.

How Should Rezdiffra Be Taken?

Rezdiffra is taken orally once daily, with or without food. The recommended dose is 80 mg daily for patients weighing less than 100 kg and 100 mg daily for those weighing at least 100 kg. Tablets must be swallowed whole without splitting, chewing, or crushing. If a dose is missed, patients should skip it and resume the next scheduled dose. Strong CYP2C8 inhibitors, such as gemfibrozil, should not be combined with Rezdiffra. When used with a moderate CYP2C8 inhibitor such as clopidogrel, lower Rezdiffra doses are required. Certain statin doses must also be limited, and clinicians monitor liver-related laboratory results during treatment.

What Are the Side Effects and Warnings of Rezdiffra?

Common adverse effects include diarrhea, nausea, itching, vomiting, constipation, abdominal discomfort, and dizziness. Serious risks include liver injury and gallbladder-related complications, including gallstones and gallbladder inflammation. Rezdiffra can increase exposure to certain statins, raising the risk of muscle injury or other statin-related adverse effects. Its use is not recommended with strong CYP2C8 inhibitors or in patients with moderate to severe liver impairment. Clinicians monitor for liver-related symptoms and changes in laboratory tests. Yellowing of the skin, dark urine, severe abdominal pain, or persistent vomiting requires prompt medical evaluation.

Common Questions About Rezdiffra

Is Rezdiffra the same as resmetirom?

Yes. Rezdiffra is the brand name for resmetirom, a thyroid hormone receptor-beta agonist approved for specified adults with MASH and liver fibrosis.

Can Rezdiffra treat all types of fatty liver disease?

No. Rezdiffra is approved for noncirrhotic MASH with moderate to advanced fibrosis, consistent with stages F2 to F3.

It Rezdiffra approved for patients with cirrhosis?

No. Its approved indication is limited to noncirrhotic MASH, and the label advises avoiding use in decompensated cirrhosis.

Can Rezdiffra be taken with statins?

Some statins may be used with Rezdiffra, but dose limits and monitoring apply to certain products because resmetirom can increase statin exposure.

References

DailyMed - REZDIFFRA (resmetirom) tablet. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e67ea09f-a840-439c-86c8-f98585f978b2. Date Accessed November 3, 2026.

Drug Trials Snapshots: REZDIFFRA. U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-rezdiffra. Date Accessed November 3, 2026.

FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease. Date Accessed November 3, 2026.

Resmetirom. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK603251/. Date Accessed November 3, 2026.

Resmetirom. MedlinePlus. https://medlineplus.gov/druginfo/meds/a624021.html. Date Accessed November 3, 2026.